Recent Analysts’ Ratings Updates for Arcus Biosciences (RCUS)

A number of research firms have changed their ratings and price targets for Arcus Biosciences (NYSE: RCUS):

• 1/18/2026 – Arcus Biosciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 1/12/2026 – Arcus Biosciences was upgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “buy” rating. They now have a $28.00 price target on the stock, up previously from $16.00.
• 1/10/2026 – Arcus Biosciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 1/8/2026 – Arcus Biosciences had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $20.00 price target on the stock, down previously from $23.00.
• 12/15/2025 – Arcus Biosciences had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 12/14/2025 – Arcus Biosciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/12/2025 – Arcus Biosciences had its “buy” rating reaffirmed by analysts at Citigroup Inc..
• 12/12/2025 – Arcus Biosciences was given a new $30.00 price target on by analysts at Truist Financial Corporation.
• 12/12/2025 – Arcus Biosciences had its price target raised by analysts at HC Wainwright from $28.00 to $32.00. They now have a “buy” rating on the stock.
• 12/6/2025 – Arcus Biosciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/28/2025 – Arcus Biosciences had its price target raised by analysts at Bank of America Corporation from $17.00 to $26.00. They now have a “neutral” rating on the stock.
• 11/22/2025 – Arcus Biosciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Insider Buying and Selling at Arcus Biosciences

In other news, President Juan C. Jaen sold 82,997 shares of Arcus Biosciences stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $24.71, for a total value of $2,050,855.87. Following the transaction, the president directly owned 954,063 shares of the company’s stock, valued at $23,574,896.73. The trade was a 8.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Terry J. Rosen sold 28,947 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total transaction of $633,360.36. Following the completion of the sale, the chief executive officer owned 2,220,553 shares of the company’s stock, valued at approximately $48,585,699.64. This trade represents a 1.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 422,060 shares of company stock worth $9,286,202 over the last 90 days. Corporate insiders own 9.60% of the company’s stock.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.